Status:
COMPLETED
Cross-sectional Study for the Identification of Blood Biomarkers in Healthy Young and Old Individuals
Lead Sponsor:
Barcelonabeta Brain Research Center, Pasqual Maragall Foundation
Collaborating Sponsors:
Göteborg University
Conditions:
Aging
Eligibility:
All Genders
18+ years
Brief Summary
Ageing is clearly the most important risk factor for AD and other dementias but, despite the amount of evidence supporting this fact, the exact mechanism that link ageing and AD is still unknown and, ...
Eligibility Criteria
Inclusion
- Men and women between 18 and 25 years (young adults group) or older than 70 for persons at the time of inclusion (old adults group).
- Subjects with no subjective cognitive complaints.
- Individuals interested in participating in the study who fully understand all the procedures that will be performed.
- Explicit participant agreement to undergo all the study procedures, which encompass:
- Collection of basic demographic data.
- Collection of a blood sample.
- Give informed consent and agree that no data resulting from the study (which is no clinically relevant) will be given to the participant
Exclusion
- No signs of subjective cognitive impairment.
- Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the protocol. Including: auditive and visual impairment, renal insufficiency under hemodialysis treatment, hepatic cirrhosis, chronic pneumopathy under oxygen therapy, solid organ transplantation, fibromyalgia, active oncologic disease under treatment (excluding localized tumours).
- Any significant major psychiatric illness (following DSM-IV diagnosis manual) o diseases that interfere with cognitive function (including major depression disorder, bipolar disorder, schizophrenia).
- Acquired brain injury: brain traumatic injury with parenchymal or extra-axial macroscopic injury, large vessel ischemic stroke or hemorrhagic stroke, brain tumors or other conditions that may cause acquired brain injury (brain radio- or chemotherapy).
- Parkinson's disease, epilepsy under treatment and with frequent seizures (\>1 /month) in the last year, multiple sclerosis or any other neurodegenerative disease.
- Researcher criteria: individuals that have any condition which, under researcher's view, could lead to difficulty complying with the protocol.
Key Trial Info
Start Date :
July 12 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2020
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT03846245
Start Date
July 12 2018
End Date
December 31 2020
Last Update
June 9 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Barcelonabeta Brain Research Center
Barcelona, Spain, 08005